// App-Quantinova.ai

P-61 : Impacts of salvage chemotherapy after nivolumab therapy (NIVO): A REVIVE substudy

Researchers

Presenter

  • H. Matsuoka

Principal Investigators

  • T. Misumi

  • Y. Sakamoto

  • T. Kawakami

  • H. Tanioka

  • T. Matsushima

  • H. Miwa

  • H. Shoji

  • A. Ishiguro

  • S. Fushida

  • K. Miura

  • T. Yamada

  • K. Shinozaki

  • T. Mizukami

  • T. Moriwaki

  • S. Mitani

  • M. Nakamura

  • K. Muro

  • T. Nishina

Medical Centers

  • FUJITA HEALTH UNIVERSITY, Toyoake, Japan

  • Saitama Cancer Center, Komuro, Japan

  • Department of Data Science, National Cancer Center Hospital East, Kashiwa, Japan

  • KAWASAKI MEDICAL SCHOOL, Kurashiki, Japan

  • Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

  • Department of Internal Medicine, Himeji Red Cross Hospital, Himeji, Japan

  • Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan

  • National Hospital Organization Shikoku Cancer Center, Ehime, Japan

  • Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan

  • Hyogo College of Medicine, Nishinomiya, Japan

  • Department of Medical Oncology, Osaki Citizen Hospital, Osaki, Japan

  • Kanagawa Cancer Center, Yokohama, Japan

  • Kindai University Faculty of Medicine, Osaka-Sayama, Japan

  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-Gun, Japan

  • Department of Gastroenterologic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

  • Department of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan

  • Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

  • Hiroshima Prefectural Hospital, Hiroshima, Japan

  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Trifluridine and Tipiracil Hydrochloride

  • Oxaliplatin

  • Irinotecan

  • Nivolumab

  • Revive

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Observational

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved